Press release
Non-Alcoholic Steatohepatitis (NASH) Market 2025-2034 Business Outlook, Critical Insight and Growth
Non-Alcoholic Steatohepatitis (NASH) Market
Non-Alcoholic Steatohepatitis (NASH) is a progressive liver disease that falls under the spectrum of non-alcoholic fatty liver disease (NAFLD). It is characterized by liver fat accumulation, inflammation, and cell damage, which can lead to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to obesity, diabetes, and metabolic syndrome, NASH has become a major global health challenge and a focus of pharmaceutical research.
Despite affecting millions worldwide, there are limited approved therapies for NASH. Most patients are managed through lifestyle interventions, but growing unmet medical needs and a strong drug development pipeline are rapidly reshaping the NASH market. With rising prevalence, increased awareness, and technological advances in diagnostics, the NASH market is positioned for substantial growth over the next decade.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71162
Market Overview
• Market Size (2024): Approximately USD 8.5 billion
• Forecast (2034): Approximately USD 21.8 billion
• CAGR (2025-2034): 9.4%
Growth Drivers:
• Rising prevalence of obesity, diabetes, and metabolic syndrome worldwide.
• Expanding drug development pipeline with late-stage clinical candidates.
• Increasing adoption of non-invasive diagnostic tools such as elastography and biomarker panels.
• Strong investment from global pharmaceutical and biotech companies.
• Government and healthcare organization initiatives for liver disease awareness and screening.
Challenges:
• Lack of widely approved therapies; most candidates remain in clinical trials.
• High cost of advanced treatments expected to limit access.
• Underdiagnosis due to asymptomatic progression in early stages.
Segmentation Analysis
The NASH market can be segmented into the following categories:
• By Drug Class:
o Farnesoid X Receptor (FXR) Agonists
o Thyroid Hormone Receptor-Beta (THR-β) Agonists
o GLP-1 Receptor Agonists
o PPAR Agonists
o Antifibrotic Agents
o Others (anti-inflammatory and antioxidant drugs)
• By Diagnostics & Technology:
o Imaging (FibroScan, MR Elastography, ultrasound)
o Biomarker-based tests (blood panels, fibrosis markers)
o Liver biopsy (still the gold standard but declining in use)
• By End Use:
o Hospitals and Clinics
o Specialty Liver Centers
o Diagnostic Laboratories
o Research Institutes
• By Application:
o NASH with Fibrosis
o NASH with Cirrhosis
o Early-stage NASH
Summary: FXR and THR-β agonists are leading therapeutic classes in clinical trials, while GLP-1 receptor agonists-already widely used in diabetes and obesity management-are gaining strong traction for NASH. Non-invasive diagnostics are gaining preference over liver biopsy, facilitating early detection and monitoring.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71162/non-alcoholic-steatohepatitis-market
Regional Analysis
• North America:
The largest market, supported by high obesity and diabetes rates, robust R&D pipelines, and early adoption of innovative therapies. The U.S. dominates, with multiple late-stage trials and regulatory incentives driving growth.
• Europe:
A major market, led by Germany, France, the UK, and Italy. Strong healthcare infrastructure and awareness of metabolic diseases support adoption of diagnostic tools and therapies.
• Asia-Pacific:
Expected to witness the fastest CAGR, fueled by rapid urbanization, changing diets, and rising rates of obesity and diabetes. China and India represent massive patient pools, while Japan and South Korea lead in research and innovation.
• Middle East & Africa:
Gradual growth due to high prevalence of obesity and diabetes. Limited access to advanced treatments remains a challenge, though healthcare investments are improving.
• Latin America:
Brazil, Mexico, and Argentina dominate the regional market, driven by lifestyle-related disease burden and expanding healthcare infrastructure.
Regional Summary: North America and Europe currently lead in revenues, but Asia-Pacific is projected to drive future growth due to its large patient base and increasing healthcare spending.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of obesity and type 2 diabetes.
• Development of late-stage drug candidates with potential blockbuster status.
• Growing use of non-invasive diagnostics for early disease detection.
• Supportive regulatory frameworks for orphan and breakthrough therapies.
Key Challenges:
• High cost of therapies limiting adoption in developing markets.
• Absence of curative treatment options.
• Difficulties in recruiting large-scale trial populations due to asymptomatic early-stage NASH.
Latest Trends:
• Shift toward combination therapies targeting multiple disease pathways.
• Expansion of AI-powered imaging tools for fibrosis assessment.
• Use of GLP-1 receptor agonists (e.g., semaglutide) repurposed from diabetes/obesity for NASH.
• Partnerships between pharmaceutical companies and diagnostic firms to improve patient screening.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71162
Competitor Analysis
Key Players:
• Madrigal Pharmaceuticals (resmetirom - THR-β agonist)
• Intercept Pharmaceuticals (FXR agonists)
• Gilead Sciences
• Novo Nordisk (GLP-1 receptor agonists)
• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Bristol Myers Squibb
• Boehringer Ingelheim
• Genfit
Competitive Landscape:
The NASH market is highly competitive and research-driven. Madrigal Pharmaceuticals has achieved regulatory breakthroughs with resmetirom, while Intercept continues to advance FXR agonists. Novo Nordisk is leveraging its diabetes/obesity expertise with GLP-1 therapies. Big pharma companies are focusing on partnerships, acquisitions, and licensing to strengthen their pipelines. Diagnostic companies are also key players, enabling early detection and patient stratification.
Conclusion
The Non-Alcoholic Steatohepatitis (NASH) Market is entering a high-growth phase, driven by rising prevalence of metabolic disorders, expansion of diagnostic tools, and strong drug pipelines. From USD 8.5 billion in 2024, the market is projected to more than double to USD 21.8 billion by 2034, expanding at a CAGR of 9.4%.
Key opportunities include:
• Fast-tracking approval of late-stage drug candidates.
• Expanding non-invasive diagnostic access in developing economies.
• Developing combination therapies for broader efficacy.
• Leveraging AI and digital health platforms for patient management.
This report is also available in the following languages : Japanese (非アルコール性脂肪肝炎市場), Korean (비알코올성 지방간염 시장), Chinese (非酒精性脂肪性肝炎市场), French (Marché de la stéatohépatite non alcoolique), German (Markt für nichtalkoholische Steatohepatitis), and Italian (Mercato della steatoepatite analcolica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71162
Our More Reports:
Moderate to Severe Inflammatory Acne Vulgaris Market
https://exactitudeconsultancy.com/reports/71424/moderate-to-severe-inflammatory-acne-vulgaris-market
Mucinoses Market
https://exactitudeconsultancy.com/reports/71426/mucinoses-market
Necrobiosis Lipoidica Diabeticorum (NLD) Market
https://exactitudeconsultancy.com/reports/71428/necrobiosis-lipoidica-diabeticorum-nld-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) Market 2025-2034 Business Outlook, Critical Insight and Growth here
News-ID: 4160083 • Views: …
More Releases from Exactitude Consultancy
Gastrointestinal Anastomosis Market Set to Witness Significant Growth by 2025-20 …
Introduction
Gastrointestinal (GI) anastomosis is a critical surgical procedure involving the connection of two segments of the digestive tract, performed after resections for conditions such as cancer, bowel obstruction, Crohn's disease, ulcerative colitis, and trauma. The procedure can be performed using surgical staplers, sutures, or advanced minimally invasive devices. With gastrointestinal cancers, inflammatory bowel disease (IBD), and obesity on the rise globally, the demand for GI anastomosis procedures is expanding rapidly.
Advancements…
Gastroesophageal Reflux Disease (GERD) Devices Market Insights and Future Outloo …
Introduction
Gastroesophageal Reflux Disease (GERD) is a chronic condition where stomach contents flow back into the esophagus, causing symptoms such as heartburn, regurgitation, chest pain, and, in severe cases, esophagitis or Barrett's esophagus. While medications like proton pump inhibitors (PPIs) are widely used for management, a growing number of patients experience refractory GERD, where pharmacological treatments fail to provide relief.
This has accelerated demand for GERD devices, which include endoscopic therapies, implantable…
Irritable Bowel Syndrome (IBS) Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by chronic abdominal pain, bloating, altered bowel habits (diarrhea, constipation, or both), and discomfort without identifiable structural abnormalities. IBS affects millions worldwide and has a significant impact on quality of life, work productivity, and healthcare costs.
The exact cause of IBS remains unclear, though it is associated with gut-brain axis dysfunction, food sensitivities, stress, and microbiome imbalances. While not life-threatening,…
Overt Hepatic Encephalopathy (OHE) Market New Product Development & Latest Trend …
Introduction
Overt Hepatic Encephalopathy (OHE) is a serious and potentially life-threatening complication of chronic liver disease, particularly cirrhosis. It results from the accumulation of neurotoxins, especially ammonia, in the bloodstream, impairing brain function. Patients present with altered mental status, confusion, motor dysfunction, and in severe cases, coma. OHE not only worsens quality of life but also increases hospitalization rates and mortality risk, representing a major healthcare challenge worldwide.
As liver diseases such…
More Releases for NASH
Nash Electrical Services Expands Electrical Solutions Across Rochester, NY
Nash Electrical Services, a trusted leader in electrical services in Rochester, NY [https://nashelectricalservices.com/], is excited to announce the expansion of its electrical services for both commercial and residential clients. Known for delivering reliable, innovative, and high-quality solutions, Nash Electrical Services continues to set the standard in the electrical industry, providing a wide array of services to meet the growing needs of the community.
Expanded Electrical Solutions and Key Areas of Expertise
With…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
